Diagnostic and prognostic value of miR-1 and miR-29b on adverse ventricular remodeling after acute myocardial infarction – The SITAGRAMI-miR analysis

Grabmaier, Ulrich; Clauß, Sebastian; Groß, Lisa; Klier, Ina; Franz, Wolfgang M.; Steinbeck, Gerhard; Wakili, Reza; Theiß, Hans; Brenner, Christoph

doi:10.1016/j.ijcard.2017.06.054

Cited by 61 publications

(50 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In order to observe the progress of disease, it is significant to discover a biological marker used to predict the adverse events for CHD patients. As the accurate biomarkers of prognosis being of increasing clinical value, more studies [3,4] evaluating their validity of prognostic value have been performed. Currently, a metabolite called trimethylamine-N-oxide (TMAO) has recently shown association with the incidence of major adverse cardiac events (MACE) in patients with CHD [5][6][7][8][9][10][11].…”

Section: Introductionmentioning

confidence: 99%

Trimethylamine-N-oxide has prognostic value in coronary heart disease: a meta-analysis and dose-response analysis

Yao

Liao

Zhao

et al. 2020

BMC Cardiovasc Disord

View full text Add to dashboard Cite

Background: Previous clinical studies have suggested that trimethylamine-N-oxide (TMAO) could contribute to the development of atherosclerosis cardiovascular disease. However, the synthetic analysis in coronary heart disease (CHD) was not yet performed. We aimed to clarify the relationship between elevated plasma concentrations of TMAO and the incidence of major adverse cardiovascular events (MACE) in CHD patients. Methods: Meta-analysis and dose-response analysis of hazard ratio data from prospective observational studies reporting on the association between TMAO plasma concentrations and the incidence of MACE in patients with CHD were conducted. Results: Of the 2369 published articles identified in the search, seven papers, with data from nine cohort studies (10,301 patients), were included in the meta-analysis. Combined data showed that elevated plasma TMAO concentrations could increase 58% higher risk of MACE in patients with CHD (hazard ratios [HR]: 1.58; 95% confidence interval [CI] = 1.35-1.84, P = 0.000). For follow-up ≥ 1 year, it was associated with 62% higher risk of MACE in patients with longer-term than shorter-term (HR for follow-up ≥ 4 years: 1.96; 95% CI = 1.52-2.52 vs one to 3 years: 1.34; 95% CI = 1.26-1.43, P = 0.004). The dose-response analysis revealed a 'J' shaped association between TMAO concentration and the incidence of MACE (P = 0.033), with the concentration above 5.1 μmol/L being associated with HR of > 1. Conclusions: Elevated levels of TMAO are associated with an increased incidence of MACE in patients with CHD. TMAO concentration of 5.1 μmol/L may be a cutoff value for prognosis.

show abstract

Section: Introductionmentioning

confidence: 99%

Trimethylamine-N-oxide has prognostic value in coronary heart disease: a meta-analysis and dose-response analysis

Yao

Liao

Zhao

et al. 2020

BMC Cardiovasc Disord

View full text Add to dashboard Cite

show abstract

“…The AUC value of post-AMI heart failure was 0.764, which was an independent predictor of heart failure after AMI [92]. Circulating miR-1 and miR-29b levels were correlated with changes in infarct volume of MRI indicators, and miR-29b levels were closely correlated with changes in left ventricular end-diastolic volume of MRI indicators [93], so increased circulating miR-1 levels could also predict the occurrence of heart failure after AMI [94].…”

Section: Micrornas As a Prognostic Marker For Acsmentioning

confidence: 86%

Noncoding RNAs as Biomarkers for Acute Coronary Syndrome

Wang

Jin

2020

BioMed Research International

View full text Add to dashboard Cite

Acute coronary syndrome (ACS), consisting of acute myocardial infarction and unstable angina, is the most dangerous and fatal form of coronary heart disease. Acute coronary syndrome has sudden onset and rapid development, which may lead to malignant life-threatening conditions at any time. Therefore, early detection and diagnosis are critical for patients with ACS. Recent studies have found that noncoding RNA is of great significance in the diagnosis and treatment of cardiovascular diseases. In this review, we summarized recent data on circulating noncoding RNAs (including microRNA, long noncoding RNA, and circular RNA) as diagnostic and prognostic markers in ACS including acute myocardial infarction and unstable angina. Specifically, microRNAs (miRNAs) as diagnostic markers are divided into three types: miRNAs of increased expression in ACS, miRNAs of decreased expression in ACS, and miRNAs of contradictory expression in ACS. Moreover, we described these miRNAs of increased expression in ACS based on miRNAs family. This review may result in a great guidance of noncoding RNAs as biomarkers for ACS in clinical practice.

show abstract

“…Altered expression of miRNAs (miR-499, miR-636, miR-380, miR-133a, miR-17, miR-21, miR-29b, miR-192, miR-194, miR-499, miR-1915, miR-34a, miR-423, miR-328, miR-134, miR-1254, miR-1, miR-181c, miR-208b, miR-566, miR-7-1, miR-92a, miR-455-3p, miR-126, miR-423-5p, miR-636, miR-486, and miR-1291 were upregulated, whereas miR-197, miR-106, and miR-223 were downregulated) have been detected in serum/plasma of patients with acute myocardial infarction and have been used as new biomarkers for predicting major adverse cardiovascular events in past studies (26). Clinical studies, including miRNAs that had both diagnostic and prognostic significance in the setting of acute myocardial infarction, are shown in Table 1 (49)(50)(51)(52)(53)(54)(55)(56). Coskunpinar et al (57) reported an increase of miR-221-3p in subjects with acute myocardial infarction, which were correlated with ejection fraction (inversely), troponin, and risk scores.…”

Section: Mirna and Acute Myocardial Infarctionmentioning

confidence: 99%

MicroRNA and Cardiovascular Diseases

Çakmak

Demir

2020

Balkan Med J

View full text Add to dashboard Cite

Cardiovascular diseases are one of the most common causes of death in both developing and developed countries worldwide. Even though there have been improvements in primary prevention, the prevalence of cardiovascular diseases continues to increase in recent years. Hence, it is crucial to both investigate the molecular pathophysiology of cardiovascular diseases in-depth and find novel biomarkers regarding the early and proper prevention and diagnosis of these diseases. MicroRNAs, or miRNAs, are endogenous, conserved, single-stranded non-coding RNAs of 21-25 nucleotides in length. miRNAs have important roles in various cellular events such as embryogenesis, proliferation, vasculogenesis, apoptosis, cell growth, differentiation, and tumorigenesis. They also have potential roles in the cardiovascular system, including angiogenesis, cardiac cell contractility, control of lipid metabolism, plaque formation, the arrangement of cardiac rhythm, and cardiac cell growth. Circulating miRNAs are promising novel biomarkers for purposes of the diagnosis and prognosis of cardiovascular diseases. Cell or tissue specificity, stability in serum or plasma, resistance to degradative factors such as freeze-thaw cycles or enzymes in the blood, and fast-release kinetics, provide the potential for miRNAs to be surrogate markers for the early and accurate diagnosis of disease and for predicting middle-or longterm prognosis. Moreover, it may be a logical approach to combine miRNAs with traditional biomarkers to improve risk stratification and long-term prognosis. In addition to their efficacy in both diagnosis and prognosis, miRNA-based therapeutics may be beneficial for treating cardiovascular diseases using novel platforms and computational tools and in combination with traditional methods of analysis. microRNAs are promising, novel therapeutic agents, which can affect multiple genes using different signaling pathways. miRNAs therapeutic modulation techniques have been used in the settings of atherosclerosis, acute myocardial infarction, restenosis, vascular remodeling, arrhythmias, hypertrophy and fibrosis, angiogenesis and cardiogenesis, aortic aneurysm, pulmonary hypertension, and ischemic injury. This review presents detailed information about miRNAs regarding structure and biogenesis, stages of synthesis and functions, expression profiles in serum/plasma of living organisms, diagnostic and prognostic potential as novel biomarkers, and therapeutic applications in various diseases.

show abstract

Diagnostic and prognostic value of miR-1 and miR-29b on adverse ventricular remodeling after acute myocardial infarction – The SITAGRAMI-miR analysis

Cited by 61 publications

References 24 publications

Trimethylamine-N-oxide has prognostic value in coronary heart disease: a meta-analysis and dose-response analysis

Trimethylamine-N-oxide has prognostic value in coronary heart disease: a meta-analysis and dose-response analysis

Noncoding RNAs as Biomarkers for Acute Coronary Syndrome

MicroRNA and Cardiovascular Diseases

Contact Info

Product

Resources

About